| Title |
A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients
|
|---|---|
| Published in |
Journal of Neuro-Oncology, October 2015
|
| DOI | 10.1007/s11060-015-1958-z |
| Pubmed ID | |
| Authors |
J. J. Raizer, P. Giglio, J. Hu, M. Groves, R. Merrell, C. Conrad, S. Phuphanich, V. K. Puduvalli, M. Loghin, N. Paleologos, Y. Yuan, D. Liu, A. Rademaker, W. K. Yung, B. Vaillant, J. Rudnick, M. Chamberlain, N. Vick, S. Grimm, I. W. Tremont-Lukats, J. De Groot, K. Aldape, M. R. Gilbert, Brain Tumor Trials Collaborative |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 61 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 2% |
| Unknown | 60 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 10 | 16% |
| Student > Ph. D. Student | 7 | 11% |
| Student > Master | 6 | 10% |
| Student > Postgraduate | 5 | 8% |
| Professor > Associate Professor | 5 | 8% |
| Other | 14 | 23% |
| Unknown | 14 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 24 | 39% |
| Biochemistry, Genetics and Molecular Biology | 7 | 11% |
| Engineering | 4 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
| Agricultural and Biological Sciences | 2 | 3% |
| Other | 6 | 10% |
| Unknown | 15 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 October 2015.
All research outputs
#21,285,712
of 26,017,215 outputs
Outputs from Journal of Neuro-Oncology
#2,612
of 3,329 outputs
Outputs of similar age
#220,227
of 298,270 outputs
Outputs of similar age from Journal of Neuro-Oncology
#49
of 80 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,329 research outputs from this source. They receive a mean Attention Score of 4.5. This one is in the 11th percentile – i.e., 11% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 298,270 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 80 others from the same source and published within six weeks on either side of this one. This one is in the 5th percentile – i.e., 5% of its contemporaries scored the same or lower than it.